N3-C5-NHS ester

CAS No. 866363-70-4

N3-C5-NHS ester ( —— )

Catalog No. M26991 CAS No. 866363-70-4

N3-C5-NHS ester is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 48 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    N3-C5-NHS ester
  • Note
    Research use only, not for human use.
  • Brief Description
    N3-C5-NHS ester is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
  • Description
    N3-C5-NHS ester is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    GABAA
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    866363-70-4
  • Formula Weight
    254.2
  • Molecular Formula
    C10H14N4O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [N-]=[N+]=NCCCCCC(=O)ON1C(=O)CCC1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Thompson SA, et al. Salicylidene salicylhydrazide, a selective inhibitor of beta 1-containing GABAA receptors. Br J Pharmacol. 2004 May;142(1):97-106.
molnova catalog
related products
  • Tetramethylammonium

    Tetramethylammonium ion has limited toxicity of dermal exposure, but fatal effects can be introduced by pre-treatment with hydroxide ion.

  • CAY10781

    CAY10781 is an inhibitor of the protein-protein interaction between neuropilin-1 (NRP-1) and VEGF-A.1It inhibits the interaction by 43% when used at a concentration of 12.5 μM. CAY10781 also inhibits VEGF-A-induced phosphorylation of VEGFR2 in catecholamine A-differentiated (CAD) cells when used at the same concentration.

  • NIBR-0213

    NIBR-0213, a potent and selective S1P(1) antagonist, has efficacy in experimental autoimmune encephalomyelitis.